Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells
Open Access
- 22 August 2018
- journal article
- letter
- Published by Springer Nature in Blood Cancer Journal
- Vol. 8 (9) , 1-6
Abstract
No abstract availableFunding Information
- Ministry of Education and Science | Fundação para a Ciência e a Tecnologia (PD/BD/52476/2013)
- Bundesministerium für Forschung, Technologie und Raumfahrt (TurbiCAR)
This publication has 15 references indexed in Scilit:
- Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironmentJournal for ImmunoTherapy of Cancer, 2017
- Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”Oncotarget, 2017
- Challenges in Antibody Development against Tn and Sialyl-Tn AntigensBiomolecules, 2015
- Adoptive cellular therapy: A race to the finish lineScience Translational Medicine, 2015
- Simultaneous targeting of prostate stem cell antigen and prostate‐specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell‐retargeting systemThe Prostate, 2014
- The Basic Principles of Chimeric Antigen Receptor DesignCancer Discovery, 2013
- Novel Humanized and Highly Efficient Bispecific Antibodies Mediate Killing of Prostate Stem Cell Antigen-Expressing Tumor Cells by CD8+ and CD4+ T CellsThe Journal of Immunology, 2012
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cellsBlood, 2012
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- A spectrum of monoclonal antibodies reactive with human mammary tumor cells.Proceedings of the National Academy of Sciences, 1981